Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers

Genes and Development

Volumn 29, Issue 21, 2015, Pages 2219-2224

  Stern, Josh Lewis ^a   Theodorescu, Dan ^b,c   Vogelstein, Bert ^d,e   Papadopoulos, Nickolas ^d,e   Cech, Thomas R ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Chromatin; Monoallelic; Noncoding mutations; Promoter; Telomerase; TERT

Indexed keywords

HISTONE H3; MESSENGER RNA; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR ELF 1; CHROMATIN; GA BINDING PROTEIN; GABPA PROTEIN, HUMAN; GABPB1 PROTEIN, HUMAN; PROTEIN BINDING; TELOMERASE;

ALLELE; ARTICLE; CHROMATIN; CONTROLLED STUDY; EPIGENETICS; GENE ACTIVATION; GENE EXPRESSION; GENE SILENCING; GENE SWITCHING; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOSITY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MULTIPLE CANCER; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION INITIATION; TRANSITIONAL CELL CARCINOMA; UPREGULATION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; MUTATION; NEOPLASM; TUMOR CELL LINE;

CELL LINE, TUMOR; CHROMATIN; EPIGENESIS, GENETIC; GA-BINDING PROTEIN TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MUTATION; NEOPLASMS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; TELOMERASE;

EID: 84946712059     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.269498.115     Document Type: Article

References (38)

1. Armanios M, Chen J-L, Chang Y-PC, Brodsky RA, Hawkins A, Griffin CA, Eshleman JR, Cohen AR, Chakravarti A, Hamosh A, et al. 2005. Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Proc Natl Acad Sci 102: 15960-15964.
2. Atkinson SP, Hoare SF, Glasspool RM, Keith WN. 2005. Lack of telomerase gene expression in alternative lengthening of telomere cells is associated with chromatin remodeling of the hTR and hTERT gene promoters. Cancer Res 65: 7585-7590.
3. Bell RJA, Rube HT, Kreig A, Mancini A, Fouse SF, Nagarajan RP, Choi S, Hong C, He D, Pekmezci M, et al. 2015. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science 348: 1036-1039.
4. Bernstein BE, Birney E, Dunham I, Green ED, Gunter C, Snyder M. 2012. An integrated encyclopedia of DNA elements in the human genome. Nature 489: 57-74.
5. Borah S, Xi L, Zaug AJ, Powell NM, Dancik GM, Cohen SB, Costello JC, Theodorescu D, Cech TR. 2015. TERT promoter mutations and telomerase reactivation in urothelial cancer. Science 347: 1006-1010.
6. Chiba K, Johnson JZ, Vogan JM, Wagner T, Boyle JM, Hockemeyer D. 2015. Cancer-associated TERT promoter mutations abrogate telomerase silencing. Elife 4: e07918.
7. Crump NT, Hazzalin CA, Bowers EM, Alani RM, Cole PA, Mahadevan LC. 2011. Dynamic acetylation of all lysine-4 trimethylated histone H3 is evolutionarily conserved and mediated by p300/CBP. Proc Natl Acad Sci 108: 7814-7819.
8. Davidovich C, Zheng L, Goodrich KJ, Cech TR. 2013. Promiscuous RNA binding by Polycomb repressive complex 2. Nat Struct Mol Biol 20: 1250-1257.
9. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, Ding M, Bamford S, Cole C, Ward S, et al. 2014. COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res 43: D805-D811.
10. Griewank KG, Murali R, Puig-Butille JA, Schilling B, Livingstone E, Potrony M, Carrera C, Schimming T, Möller I, Schwamborn M, et al. 2014. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. J Natl Cancer Inst 106: dju246.
11. Gugneja S, Virbasius JV, Scarpulla RC. 1995. Four structurally distinct, non-DNA-binding subunits of human nuclear respiratory factor 2 share a conserved transcriptional activation domain. Mol Cell Biol 15: 102-111.
12. Guin S, Pollard C, Ru Y, Ritterson Lew C, Duex JE, Dancik G, Owens C, Spencer A, Knight S, Holemon H, et al. 2014. Role in tumor growth of a glycogen debranching enzyme lost in glycogen storage disease. J Natl Cancer Inst 106: dju062.
13. Hollenhorst PC, McIntosh LP, Graves BJ. 2011. Genomic and biochemical insights into the specificity of ETS transcription factors. Annu Rev Biochem 80: 437-471.
14. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, et al. 2013. TERT promoter mutations in familial and sporadic melanoma. Science 339: 959-961.
15. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. 2013. Highly recurrent TERT promoter mutations in human melanoma. Science 339: 957-959.
16. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, Friedman AH, Friedman H, Gallia GL, Giovanella BC, et al. 2013. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci 110: 6021-6026.
17. Kilpinen H, Waszak SM, Gschwind AR, Raghav SK, Witwicki RM, Orioli A, Migliavacca E, Wiederkehr M, Gutierrez-Arcelus M, Panousis NI, et al. 2013. Coordinated effects of sequence variation on DNAbinding, chromatin structure, and transcription. Science 342: 744-747.
18. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. 1994. Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015.
19. Kinde I, Munari E, Faraj SF, Hruban RH, Schoenberg M, Bivalacqua T, Allaf M, Springer S, Wang Y, Diaz LA, et al. 2013. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res 73: 7162-7167.
20. LaMarco K, Thompson C, Byers B, Walton E, McKnight S. 1991. Identification of Ets-and notch-related subunits in GA binding protein. Science 253: 789-792.
21. Li L, Clevers H. 2010. Coexistence of quiescent and active adult stem cells in mammals. Science 327: 542-545.
22. Li C, Wu S, Wang H, Bi X, Yang Z, Du Y, He L, Cai Z, Wang J, Fan Z. 2015. The C228T mutation of TERT promoter frequently occurs in bladder cancer stem cells and contributes to tumorigenesis of bladder cancer. Oncotarget 6: 19542-19551.
23. Liu C, Fang X, Ge Z, Jalink M, Kyo S, Björkholm M, Gruber A, Sjöberg J, Xu D. 2007. The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3. Cancer Res 67: 2626-2631.
24. McVicker G, van de Geijn B, Degner JF, Cain CE, Banovich NE, Raj A, Lewellen N, Myrthil M, Gilad Y, Pritchard JK. 2013. Identification of genetic variants that affect histone modifications in human cells. Science 342: 747-749.
25. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, et al. 1997. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90: 785-795.
26. Rachakonda PS, Hosen I, de Verdier PJ, Fallah M, Heidenreich B, Ryk C, Wiklund NP, Steineck G, Schadendorf D, Hemminki K, et al. 2013. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci 110: 17426-17431.
27. Sawada J, Goto M, Sawa C, Watanabe H, Handa H. 1994. Transcriptional activation through the tetrameric complex formation of E4TF1 subunits. EMBO J 13: 1396-1402.
28. Schuettengruber B, Martinez A-M, Iovino N, Cavalli G. 2011. Trithorax group proteins: switching genes on and keeping them active. Nat Rev Mol Cell Biol 12: 799-814.
29. Schwartz JC, Ebmeier CC, Podell ER, Heimiller J, Taatjes DJ, Cech TR. 2012. FUS binds the CTD of RNA polymerase II and regulates its phosphorylation at Ser2. Genes Dev 26: 2690-2695.
30. Stasevich TJ, Hayashi-Takanaka Y, Sato Y, Maehara K, Ohkawa Y, Sakata-Sogawa K, Tokunaga M, Nagase T, Nozaki N, McNally JG, et al. 2014. Regulation of RNA polymerase II activation by histone acetylation in single living cells. Nature 516: 272-275.
31. Steffen PA, Ringrose L. 2014. What are memories made of? How Polycomb and Trithorax proteins mediate epigenetic memory. Nat Rev Mol Cell Biol 15: 340-356.
32. Stern JL, Zyner KG, Pickett HA, Cohen SB, Bryan TM. 2012. Telomerase recruitment requires both TCAB1 and Cajal bodies independently. Mol Cell Biol 32: 2384-2395.
33. Vinagre J, Almeida A, Pópulo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, et al. 2013. Frequency of TERT promoter mutations in human cancers. Nat Commun 4: 2185.
34. Weinhold N, Jacobsen A, Schultz N, Sander C, Lee W. 2014. Genome-wide analysis of noncoding regulatory mutations in cancer. Nat Genet 46: 1160-1165.
35. Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW. 1996. Telomerase activity in human germline and embryonic tissues and cells. Dev Genet 18: 173-179.
36. Xi L, Schmidt JC, Zaug AJ, Ascarrunz DR, Cech TR. 2015. A novel twostep genome editing strategy with CRISPR-Cas9 provides new insights into telomerase action and TERT gene expression. Genome Biol 16: 231.
37. Yan H, Yuan W, Velculescu VE, Vogelstein B, Kinzler KW. 2002. Allelic variation in human gene expression. Science 297: 1143.
38. Zhu J, Zhao Y, Wang S. 2010. Chromatin and epigenetic regulation of the telomerase reverse transcriptase gene. Protein Cell 1: 22-32.